Treatment With SU11248 in Patients With Neuroendocrine Tumors

A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor

To assess the safety and efficacy of SU11248 in patients with Neuroendocrine Tumors.

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of carcinoid tumor or pancreatic islet cell tumor.
• Evidence of unidimensionally measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST).
• ECOG performance status 0 or 1

Exclusion Criteria:

• Diagnosis of small-cell carcinoma, pheochromocytoma/paraganglioma, Merkel cell carcinoma, or any other second malignancy within the last 5 years except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri.
• Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted.